Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BCAL DiagnosticsASX:BDX -5.33% EV-to-FCF is -4.07 as of Jul. 21, 2026. The stock has 3 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 1010100% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BCAL Diagnostics's Enterprise Value is A$26.29 Mil.
BCAL Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.46 Mil. Therefore, BCAL Diagnostics's EV-to-FCF for today is -4.07.
The historical rank and industry rank for BCAL Diagnostics's EV-to-FCF or its related term are showing as below:
ASX:BDX'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.53 Med: 0 Max: 0
Current: -4.53
ASX:BDX's EV-to-FCF is ranked worse than 100% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.84
vs ASX:BDX: -4.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BCAL Diagnostics's PE Ratio (TTM) for today is calculated as:
BCAL Diagnostics's share price for today is A$0.071.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BCAL Diagnostics EV-to-FCF Related Terms
BCAL Diagnostics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BCAL Diagnostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's EV-to-FCF falls into.
BCAL Diagnostics's current Enterprise Value is A$26.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a EV-to-FCF of -4.07 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry.
Is BCAL Diagnostics' EV-to-FCF too high?
BCAL Diagnostics' current EV-to-FCF is -4.07. Based on the distribution chart, BCAL Diagnostics ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #999999 out of 99 companies for EV-to-FCF. This places BCAL Diagnostics in the lower half of its industry. The industry median EV-to-FCF is 26.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.84, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current EV-to-FCF is -4.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current EV-to-FCF of -4.07. The current EV-to-FCF is -4.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current EV-to-FCF is -4.07 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 
